v3.25.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities      
Net loss $ (51,641) $ (50,420) $ (61,685)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 7,506 5,297 5,133
Stock-based compensation 20,698 22,254 16,458
Provision for credit losses and inventory 6,515 2,449 1,440
Amortization of operating lease right-of-use assets 1,237 723 734
Amortization of debt discount and issuance costs 1,289 1,147 1,116
Deferred income taxes 21 (21) 5
Revaluation of contingent royalty obligation payable to Evolus Founders (6,381) 7,176 4,257
Non-cash in-process research and development expense 0 0 4,429
Other adjustments to operating activities 967 36 0
Changes in operating assets and liabilities:      
Inventories (11,124) 3,252 4,193
Accounts receivable (11,509) (19,602) (9,521)
Prepaid expenses (355) 2,351 (1,798)
Accounts payable 10,103 391 (1,017)
Accrued expenses (6,364) 6,978 9,019
Accrued litigation settlement 0 0 (5,000)
Operating lease liabilities (758) (716) (907)
Other operating assets (2,469) 706 (864)
Net cash used in operating activities (42,265) (17,999) (34,008)
Cash flows from investing activities      
Purchases of property and equipment (3,441) (1,472) (473)
Additions to capitalized software (5,011) (3,351) (1,154)
Net cash used in investing activities (8,452) (4,823) (1,627)
Cash flows from financing activities      
Payment of contingent royalty obligation to Evolus Founders (6,202) (7,441) (5,537)
Proceeds from issuance and modification of debt instruments 25,000 0 50,000
Payments for debt modification fees and debt issuance costs (2,610) 0 (46)
Proceeds from follow-on offering 0 51,211 0
Payments for offering costs 0 (248) 0
Issuance of common stock in connection with incentive equity plan 1,164 4,882 231
Payment of finance lease obligations (15) 0 0
Tax withholding paid on behalf of employees for net share settlement 0 (990) (7)
Net cash provided by financing activities 17,337 47,414 44,641
Effect of exchange rates on cash and cash equivalents 254 (478) (90)
Net increase (decrease) in cash and cash equivalents (33,126) 24,114 8,916
Cash and cash equivalents, beginning of period 86,952 62,838 53,922
Cash and cash equivalents, end of period 53,826 86,952 62,838
Supplemental disclosure of cash flow information      
Cash paid for interest 14,792 17,545 12,708
Cash paid for income taxes 1,215 235 117
Non-cash investing and financing information      
Capital expenditures included in accounts payable and accrued expenses 695 252 43
Issuance of common stock in connection with Symatese Europe Agreement $ 0 $ 0 $ 1,476